EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis

Naruhiko Kamogawa iD, Kazunori Toyoda iD, Takenori Yamaguchi iD, Hiroshi Inoue iD, Takeshi Yamashita iD, Shinya Suzuki iD, Hiroaki Kobayashi, Kaori Miwa iD, Sohei Yoshimura iD, Manabu Inoue iD, Masafumi Ihara iD, Tetsuro Ago iD und 2 weitere

Journal of the American Heart Association · 17.03.2026 · 15 (6)

DOI: 10.1161/jaha.125.047724 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 17.03.2026. Verfasst von Naruhiko Kamogawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Platelet Aggregation Inhibitors, Stroke. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to evaluate the impact of concomitant use of oral anticoagulants (OAC) and antiplatelet drugs (APD) on clinical outcomes compared with OAC monotherapy in patients aged ≥75 years with atrial fibrillation.

Methods

The ANAFIE (All Nippon AF [Atrial Fibrillation] in Elderly) Registry was a prospective multicenter observational study in Japan. This subanalysis included patients aged ≥75 years with nonvalvular atrial fibrillation receiving OAC. Patients were classified into OAC monotherapy and concomitant OAC+APD therapy groups. Clinical outcomes, including stroke/systemic embolism, major bleeding, and all‐cause mortality, were compared using Cox proportional hazards models. Within the OAC+APD group, outcomes were also compared between patients using direct OACs and those using warfarin.

Results

Among 29 818 patients (median age 81 years, 42.3% female), 4861 (16.3%) received OAC+APD therapy. This group had higher proportion of men, previous cerebrovascular disease, and previous myocardial infarction. The group showed increased risk of cardiovascular death [1.57 versus 0.94/100 person‐years, adjusted hazard ratio (aHR), 1.29 [95% CI, 1.01–1.64]. There were no significant differences in stroke/systemic embolism, major bleeding, or all‐cause mortality. Within the OAC+APD group, direct OAC use was associated with lower risks of stroke/systemic embolism (aHR, 0.55 [95% CI, 0.38–0.80]), intracranial hemorrhage (aHR, 0.52 [95% CI, 0.30–0.90]), and all‐cause mortality (aHR, 0.73 [95% CI, 0.58–0.91]) compared with warfarin.

Conclusions

In older patients with atrial fibrillation, OAC+APD therapy was associated with higher incidence of cardiovascular death than OAC monotherapy, without significant differences in other clinical outcomes. For patients requiring combination therapy, DOACs may be preferable to warfarin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsPlatelet Aggregation InhibitorsStrokeHumansFemaleMaleAged, 80 and overJapanAgedRegistriesProspective StudiesHemorrhageDrug Therapy, CombinationRisk FactorsTreatment OutcomeAdministration, OralEmbolismWarfarinAge Factors

Stichwörter der Autor:innen

antiplatelet drugatrial fibrillationoral anticoagulant

Substanzen

AnticoagulantsPlatelet Aggregation InhibitorsWarfarin

Autor:innen und Institutionen

  • Department of Cerebrovascular Medicine National Cerebral and Cardiovascular Center Suita Japan.
  • Saiseikai Toyama Hospital Toyama Japan.
  • The Cardiovascular Research Institute Tokyo Japan.
  • Primary Medical Science Department Daiichi Sankyo Tokyo Japan.
  • Department of Neurology National Cerebral and Cardiovascular Center Suita Japan.
  • Department of Medicine and Clinical Science Graduate School of Medicine Sciences, Kyushu University Fukuoka Japan.

ORCID-Profile: Naruhiko Kamogawa, Kazunori Toyoda, Takenori Yamaguchi, Hiroshi Inoue, Takeshi Yamashita, Shinya Suzuki, Kaori Miwa, Sohei Yoshimura, Manabu Inoue, Masafumi Ihara, Tetsuro Ago, Masatoshi Koga

Zitieren

APA

Kamogawa, N., Toyoda, K., Yamaguchi, T., Inoue, H., Yamashita, T., Suzuki, S., Kobayashi, H., Miwa, K., Yoshimura, S., Inoue, M., Ihara, M., Ago, T., Koga, M., & ANAFIE investigators (2026). Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. Journal of the American Heart Association, 15(6). https://doi.org/10.1161/jaha.125.047724

Vancouver

Kamogawa N, Toyoda K, Yamaguchi T, Inoue H, Yamashita T, Suzuki S, et al. Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. Journal of the American Heart Association. 2026;15(6). doi:10.1161/jaha.125.047724

BibTeX
@article{Kamogawa2026,
  author = {Kamogawa, Naruhiko and Toyoda, Kazunori and Yamaguchi, Takenori and Inoue, Hiroshi and Yamashita, Takeshi and Suzuki, Shinya and Kobayashi, Hiroaki and Miwa, Kaori and Yoshimura, Sohei and Inoue, Manabu and Ihara, Masafumi and Ago, Tetsuro and Koga, Masatoshi and ANAFIE investigators, ANAFIE investigators},
  title = {Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1161/jaha.125.047724}
}
Kostenlos starten →